Max Planck Institute for Human Cognitive and Brain Sciences
Leipzig, Saxony, 04103, Germany
Location status: Recruiting
NCT Number: NCT07501377
People living with obesity have a higher risk of late-life cognitive decline and developing dementia. In women, the risk of cognitive decline may further raise during the menopausal transition, a period of substantial hormonal and metabolic changes.
Recent studies suggest that a healthy diet could help to prevent neurocognitive disorders by reducing inflammatory processes in the body and brain. Emerging evidence further indicates that the gut-brain axis and the intestinal microbiome play a crucial role in mediating this effect, through metabolic, immune, neuronal and vascular routes. Modifying the gut microbiota may thus counteract the heightened systemic inflammation seen in obesity and during menopausal transition to eventually benefit brain health.
Specifically, plant-based nutirents, such as fibre and polyphenols, have microbiome-changing, anti-inflammatory and neuroprotective properties that may slow brain aging and neuro-inflammation. However, evidence from human interventional studies and knowledge on the underlying mechanisms remain scarce.
This randomized controlled trial will therefore test whether altering gut bacteria through six months of daily intake of a personalized "polybiotic" dietary formula, compared to placebo, improves markers of brain health in women during the perimenopausal transition that are living with overweight or obesity. We plan to enroll 120 women aged 35-60 with overweight/obesity and elevated inflammatory blood markers, randomized to: intervention (7.5 or 15 g inulin, plus 200 mg resveratrol and 320 mg quercetin per day in powder form with main meals) or control (isocaloric maltodextrin). Exclusions include type 1 diabetes, current psychiatric/gastrointestinal disorders, and magentic resonance imaging (MRI) contraindications.
Before and after 26 weeks, participants will undergo brain MRI to assess inflammation-related brain markers, neuropsychological testing, anthropometric measurements, they will fill in a set of questionnaires and donate stool and blood. Gut bacteria will be profiled by next-generation sequencing; metabolites will be measured in blood and stool. The primary outcome is a proxy of neuroinflammation in the white matter assessed using diffusion-weighted MRI. Secondary analyses will examine blood-brain-barrier permeability and other functional and structural MRI measures, including MR spectoscropy. Mechanistic links among changes in inflammatory markers, microbiota composition, and short-chain fatty acids will be explored using path and network models.
This study may help to develop novel prevention and treatment strategies to mitigate obesity-related cognitive decline via the gut-brain axis.
Interested in participating?
Request Info35 year–60 year
Female
Interventional
Not applicable
Leipzig, Saxony, 04103, Germany
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
7.5g or 15g of inulin + 200mg resveratrol + 320mg quercetin in a powder formula
Equicaloric maltodextrin in powder form
Time frame: 6 months
Free water (measured using multi-shell diffusion-weighted MRI at 3 Tesla) reflects extra-cellular water which can be considered an indicator of tissue edema and impaired blood brain barrier
Time frame: 6 months
Water exchange rate over the blood-brain barrier will be measured using motion-compensated diffusion-weighted pseudo-continuous arterial-spin labeling (MCDW-ASL) or diffusion-prepared pCASL (DP-pCASL).
Time frame: 6 months
microglial activity will be quantified by measuring ADCCholine using diffusion-weighted magnetic resonance spectroscopy (dwMRS)
Time frame: 6 months
microstructure will be assessed by mean diffusivity (MD)
Time frame: 6 months
California Verbal Learning Task
Time frame: 6 months
Alpha/Beta diversity and abundance of specific bacteria (e.g. bifidobacteria) from microbiome shotgun sequencing
Time frame: 6 months
assessed using multi-shell diffusion-weighted MRI at 3T
Time frame: 6 months
Dprime and accuracy, reaction time of Mnemonic Similarity Task (MST)
Time frame: 6 months
Composite score of executive function tests derived from Trail Making Test, Attention Network Test, Stroop-Test
Time frame: 6 months
hsCRP measured in fasting blood
Time frame: 6 months
ratio of waist circumeference to hip circumference (measured)
Time frame: 6 months
A composite score based on self-reported information provided through diet protocol and food frequency questionnaire (FFQ)
Time frame: 6 months
severity of menopausal symptoms based on a questionnaire
Time frame: 6 months (during 2 weeks at baseline, and follow-up, respectively)
via wearables - smart devices finger ring and/or watch and glucose patch
Time frame: 6 months
Age, sex/gender, medical history, reproductive history, medication
Time frame: 6 months
Oxygen consumption and CO2 production measured in a metabolic chamber, determining 24-hour total energy expenditure (TEE)
Time frame: 6 months
measured using bioelectrical impedance analysis (BIA)
Time frame: 6 months
area under the curve (pre- to postprandial) of glukagon-like peptide 1 (GLP-1)
Time frame: 6 months
Follicle-stimulating hormon (FSH) measured in blood
Max Planck Institute for Human Cognitive and Brain Sciences
Other
Effects of a Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Obesity
Acronym: INFLAME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07595549
Body Weight, Diabetes Mellitus
Modesto, California, United States
View Trial DetailsNCT07575932
Body Weight, Nutrition Disorders
Chandler, Arizona, United States
View Trial DetailsNCT07243171
Body Weight, Nutrition Disorders
Beijing, Beijing Municipality, China
View Trial DetailsNCT07075146
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Mexico City, Mexico
View Trial Details